Niclosamide Therapy for Tapeworm Infections

Field: Pharmacology, Toxicology and Pharmaceutics (Life Sciences)

Editorials1 April 1985Niclosamide Therapy for Tapeworm InfectionsRICHARD D. PEARSON, M.D., ERIK L. HEWLETT, M.D.RICHARD D. PEARSON, M.D., ERIK L. HEWLETT, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-4-550 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNiclosamide [N-(2′-chloro-4′-nitrophenyl)-5-chlorosalicylamide] was developed at Bayer A. G. (1-3) and initially shown to be effective against Hymenolepis diminuta, the rat tapeworm, a cestode that occasionally infects humans. Subsequent studies in animals and humans showed that niclosamide was poorly absorbed and non-toxic after oral administration (2) and that it was active against a number of tapeworms that infect humans. Niclosamide is also used in veterinary practices and as a molluscicide.Niclosamide first became commercially available outside the United States in 1961 (Yomesan; Bayer A.G., Wuppertal, West Germany), but until recently it could be obtained in this country only as an investigational...References1. GÖNNERTSCHRAUFSTÄTTER VE. Experimentelle Untersuchungen mit N-(2′-Chlor-4′-Nitrophenyl)-5-Chlorsalicylamid, einem neuen Bandwurmmittel: 1. Mitteilung: chemotherapeutische Versuche. Arzneimittelforsch. 1960;10:881-4. MedlineGoogle Scholar2. HECHTGLOXHUBER VC. Experimentelle Untersuchungen mit N-(2′-Chlor-4′-Nitrophenyl)-5-Chlorsalicylamid, einem neuen Bandwurmmittel: 2. Mitteilung: toxikologische Untersuchungen. Arzneimittelforsch. 1960;10:884-5. MedlineGoogle Scholar3. GÖNNERTJOHANNISSCHRAUFSTÄTTERSTRUFE RJER. Konstitution und Cestocide Wirkung in der Yomesan-Reihe. Medizin Chem (Leverkusen, Ger.). 1963;7:540-67. Google Scholar4. PERERAWESTERNSCHULTZ DKM. Niclosamide treatment of cestodiasis: clinical trials in the United States. Am J Trop Med Hyg. 1970;19:610-2. CrossrefMedlineGoogle Scholar5. BROWNNEVA HF. Basic Clinical Parasitology. 5th ed. Norwalk, Connecticut: Appleton-Century-Crofts; 1983:175-90. Google Scholar6. ABRAMSSTEFTELHEINZ GHH. The treatment of human tapeworm infections with 'Yomesan.' S Afr Med J. 1963;37:6-8. MedlineGoogle Scholar7. AHKAMIHADJIAN SA. The appearance of the scolex of Taenia saginata in the stool after the eradication of the parasite by niclosamide. Z Tropenmed Parasitol. 1969;20:341 -5. MedlineGoogle Scholar8. LENGYELBANKILEVAI AGJ. Data on the symptomatology and treatment of taeniasis. Indian J Med Res. 1969;57:699-705. MedlineGoogle Scholar9. NAGATYRIFAATSALEM HMS. Clinical trials with 'Yomesan' in Hymenolepis nana infection. J Trop Med Hyg. 1962;65:128-9. MedlineGoogle Scholar10. GHERMAN I. [Observations on the treatment of taeniasis with niclosamide.] Bull Soc Pathol Exot. 1968;61:432-4. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Virginia School of Medicine Charlottesville, Virginia PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDrug discovery efforts toward inhibitors of canonical Wnt/β-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010–2020)The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infectionAdvances in the treatment, diagnosis, control and scientific understanding of taeniid cestode parasite infections over the past 50 yearsNitro-Deficient Niclosamide Confers Reduced Genotoxicity and Retains Mitochondrial Uncoupling Activity for Cancer TherapyContrasting physiological responses between invasive sea lamprey and non-target bluegill in response to acute lampricide exposureCanonical Wnt Signaling Drives Myopia Development and Can Be Pharmacologically ModulatedRepurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3βMetformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal CancerStructure–Activity Study of Nitazoxanide Derivatives as Novel STAT3 Pathway InhibitorsApplication of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infectionSignalling and putative therapeutic molecules on the regulation of synoviocyte signalling in rheumatoid arthritispH-responsive delivery of anti-metastatic niclosamide using mussel inspired polydopamine nanoparticlesInterferon-inducer antivirals: Potential candidates to combat COVID-19Human diphyllobothriasis – Authors' replyPrevention of algaculture contamination using pesticides for biofuel productionCurrent therapies under investigation for COVID-19: potential COVID-19 treatmentsRepurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?Human taeniasis infection (Taenia saginata): a complex public health problem. Case reportRepurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathwayRecent Drug-Repurposing-Driven Advances in the Discovery of Novel AntibioticsSAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathwayContributions of Hepatic and Intestinal Metabolism to the Disposition of Niclosamide, a Repurposed Drug with Poor BioavailabilityThe in vitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogensNew life for an old drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii RH strainClustering of Necropsy-Confirmed Porcine Cysticercosis Surrounding Taenia solium Tapeworm Carriers in PeruIdentification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotypeHost-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiotaIdentification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growthNiclosamide, a Drug with Many (Re)purposesA phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerAntiparasitics (PC)High-Throughput Screening and Quantitative Chemical Ranking for Sodium-Iodide Symporter Inhibitors in ToxCast Phase I Chemical LibraryNiclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathwaysAntiparasitic AgentsNiclosamide: Beyond an antihelminthic drugActivity of a novel protonophore against methicillin-resistant Staphylococcus aureusBenzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasisNiclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetesNiclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growthNiclosamide blocks glucagon phosphorylation of Ser552 on β-catenin in primary rat hepatocytes via PKA signallingAn FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)Existing drugs and their application in drug discovery targeting cancer stem cellsStructure–activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposureAssessing occupational exposure to sea lamprey pesticidesCysticercosis: A Preventable, but Embarrassing Neglected Disease Still Prevalent in Non-Developed CountriesDrugs for HelminthsRepurposing drugs for the treatment and control of helminth infectionsSensitive Voltammetric Determination of Niclosamide at a disposable pencil graphite electrodeAntihelminthic niclosamide modulates dendritic cells activation and functionCYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitroSmall molecule modulators of Wnt/β-catenin signalingDiphyllobothrium pacificum Infection is Seldom Associated with Megaloblastic AnemiaGrowth Inhibition of Ovarian Tumor–Initiating Cells by NiclosamideDetection of Taenia solium Taeniasis Coproantigen Is an Early Indicator of Treatment Failure for TaeniasisAntiparasitic AgentsAntihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC MutationsChemotherapy of Parasitic DiseasesAgents Active against Parasites and PneumocystisThe Anti-Helminthic Niclosamide Inhibits Wnt/Frizzled1 SignalingThe Nepalese ShepherdAntiparasitic AgentsSeafood ToxidromesTaeniasis/cysticercosis trend worldwide and rationale for controlNiclosamide: Comprehensive ProfileSpecies identification after treatment for human taeniasisAdverse Drug Reactions to AnthelminticsDiagnosis, treatment and control of Taenia solium cysticercosisTaenia solium cysticercosisTAPEWORMS (CESTODIASIS)Parasitic InfectionsThe zoonotic Taeniae of AfricaParasitic Infections: Therapeutic ConsiderationsLarge-Scale Use of Chemotherapy of Taeniasis as a Control Measure for Taenia Solium InfectionsNew drugs for old diseases Recent advances in antiparasitic chemotherapy 1 April 1985Volume 102, Issue 4Page: 550-551KeywordsOral administration Issue Published: 1 April 1985 PDF DownloadLoading ...